Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$240.74
▼ $3.10 (-1.3%)
Market data updated: 09/19 03:11 AM
Fundamentals updated: 09/18/2026
News analyzed: 09/19/2026
Market Cap
$15.63B
Day Range
$238.98 - $244.55
52-Week Range
$125.79 - $266.38
Beta
—
Next Earnings
03.11.2026
Support
$233.46
Resistance
$266.38
JAZZ is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+88.2% (1Y)
Strengths: 5/29 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
DCF Fair Value
Estimated fair value: $292.11 vs. price $240.74 (+21.3%)
Fair Value
Biggest negative driver
Operating margin
Operating margin: -10.1% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
45
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
34
Quality
42
Value
62
Momentum
38
Risk
56
Sentiment
80
Fundamental
30
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Jazz Pharmaceuticals plc has primarily centered on its **Ziihera drug**, which demonstrated a statistically significant overall survival benefit over trastuzumab in the Phase 3 HERIZON-GEA-01 trial, raising potential questions about whether it could replace trastuzumab as a first-line treatment for HER2-positive breast cancer. Additionally, the company’s stock performance—including a 6.9% decline since its last earnings report—has been analyzed, alongside discussions on its valuation as a potential value stock. Investor conferences and a rare pediatric drug designation for another asset (QRX003) were also briefly noted.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Jazz Pharmaceuticals plc. News trend score: 80. Reason: 7 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
18
🎯 Conviction (vs. Emotion)
34
Psychology
54
Fundamentals
30
Technical
38
Valuation
62
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+9%
Market Narrative
41
Fundamental Reality
34
Narrative Gap
+7
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market’s dominant anchoring behavior suggests traders are fixating on JAZZ’s proximity to support (0.4% above), likely due to its technical proximity to a psychological level. The narrative gap (48 vs. 34) hints at a disconnect where optimism (e.g., positive news) outweighs fundamental valuation (-18% DCF discount). Low FOMO and herding scores imply limited contagion, while muted panic signals no distress. The key question: will traders hold near support, or will the gap between narrative and reality widen further?
Updated: 09/09/2026, 05:15 AM
What could change this?
👥 What the crowd believes
"Ziihera plus chemotherapy produced a statistically significant and clinically meaningful overall-survival benefit over trastuzumab"
"Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences"
"Jazz (JAZZ) Down 6.9% Since Last Earnings Report"
"Jazz Pharmaceuticals stands out in value screens with a 9/10 valuation score"
📈 13D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 69/100
🔴 Weakest match
Thorstein Veblen — 12/100
🗣️ Why do they disagree?
The stark divide in verdicts for JAZZ reflects deep methodological disagreements about what makes a stock attractive. Samuel Armstrong Nelson’s near-perfect score suggests he sees a cyclical opportunity where the stock is oversold, aligning with his contrarian, momentum-driven approach. In contrast, Fisher, Veblen, and Lynch—who prioritize sustainable growth or intrinsic value—reject it outright, scoring it among the lowest, as the stock fails to meet their rigorous quality or valuation thresholds. Meanwhile, efficiency-market skeptics like Malkiel and Bogle see little edge over passive indexing, while Marks and Bagehot strike a cautious middle ground, acknowledging potential but tempering it with concerns about overvaluation or liquidity. Livermore’s outright negative trend verdict further polarizes the debate, framing the stock as a contrarian’s dream or a speculative trap depending on one’s bias.
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 69
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 64
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 57
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 56
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟡 47
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 46
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 41
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 37
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 36
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 32
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 19
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 18
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 15
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 12
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 12
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 6 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
A trading range after an advance, but still without clear (volume-based) confirmation of a distribution phase.
Low confidence
$233.46
Range Bottom
$266.38
Range Top
50
Trading Days in Range
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-10.1%
Net Margin
-8.3%
EBITDA Margin
-9.1%
ROE
-8.2%
ROA
-3.1%
ROIC
—
EPS
-$5.84
Cash
$1.39B
Total Debt
$5.36B
Current Ratio
1.86
Debt/Equity
1.24
How is Fair Value calculated? →
Current Price
$240.74
Estimated Fair Value (DCF)
$292.11
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
+21.3%
🟢 Appears cheap relative to estimated value
Year 1 Growth Rate
5.3%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 5.3% | $1.37B | $1.25B |
| 2 | 4.6% | $1.43B | $1.20B |
| 3 | 3.9% | $1.48B | $1.15B |
| 4 | 3.2% | $1.53B | $1.08B |
| 5 | 2.5% | $1.57B | $1.02B |
Base FCF (last actual year)
$1.30B
Terminal Value
$24.74B
Present Value of Terminal Value
$16.08B
Enterprise Value
$21.78B
Net Debt
$3.97B
Equity Value
$17.81B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$70.82
Tangible Book Value per Share (Tangible NAV)
-$31.82
Sentiment based on basic keywords (not AI) — 7 positive, 11 neutral, 2 negative out of the last 20 articles.
Yahoo · 18.9.2026
Yahoo · 18.9.2026
SeekingAlpha · 16.9.2026
SeekingAlpha · 15.9.2026
Simply Wall St. · 14.9.2026
Yahoo · 14.9.2026
StockStory · 12.9.2026
Yahoo · 12.9.2026
StockStory · 11.9.2026
Yahoo · 11.9.2026
MT Newswires · 11.9.2026
Yahoo · 11.9.2026
MT Newswires · 11.9.2026
Benzinga · 11.9.2026
Yahoo · 10.9.2026
SeekingAlpha · 10.9.2026
Benzinga · 10.9.2026
SeekingAlpha · 9.9.2026
StockStory · 8.9.2026
Yahoo · 8.9.2026
Jazz Pharmaceuticals plc (JAZZ) currently has a StockIQ AI score of 45/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
JAZZ currently scores 45/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, JAZZ's estimated fair value is $292.11, which is 21.3% above the current price of $240.74. This is one valuation model among several signals in the fair-value category, not a price target.
JAZZ's technical score is 38/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Estimated fair value: $292.11 vs. price $240.74 (+21.3%); Current ratio: 1.86; Price is above the 200-day average.
Based on the real signals StockIQ computed: Operating margin: -10.1% (negative); Net margin: -8.3% (negative); Operating margin is eroding over time.
StockIQ has no recorded dividend payment history for JAZZ.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 2 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| COZADD BRUCE C | Open Market Sale | 1.9.2026 | 6,000 | -6,000 | $250.13 |
| Kennedy Patrick | Tax Withholding in Shares | 31.8.2026 | 1,840 | -1,840 | $241.39 |
| Smith Mark Douglas | Tax Withholding in Shares | 31.8.2026 | 1,692 | -1,692 | $241.39 |
| McSharry Heather Ann | Tax Withholding in Shares | 31.8.2026 | 15 | -15 | $244.64 |
| Henderson Mary Elizabeth | Tax Withholding in Shares | 31.8.2026 | 2,076 | -2,076 | $241.39 |
| Kennedy Patrick | Tax Withholding in Shares | 31.8.2026 | 15 | -15 | $244.06 |
| COZADD BRUCE C | Tax Withholding in Shares | 31.8.2026 | 10 | -10 | $244.06 |
| LOVE TED W | Tax Withholding in Shares | 31.8.2026 | 737 | -737 | $241.39 |
| McSharry Heather Ann | Tax Withholding in Shares | 31.8.2026 | 1,840 | -1,840 | $241.39 |
| LOVE TED W | Tax Withholding in Shares | 31.8.2026 | 6 | -6 | $244.06 |
| Cook Jennifer E. | Tax Withholding in Shares | 31.8.2026 | 14 | -14 | $244.06 |
| ENRIGHT PATRICK G | Tax Withholding in Shares | 31.8.2026 | 1,692 | -1,692 | $241.39 |
| Smith Mark Douglas | Tax Withholding in Shares | 31.8.2026 | 14 | -14 | $244.64 |
| RIEDEL NORBERT G | Tax Withholding in Shares | 31.8.2026 | 1,692 | -1,692 | $241.39 |
| Winningham Rick E | Tax Withholding in Shares | 31.8.2026 | 14 | -14 | $244.64 |
| Cook Jennifer E. | Tax Withholding in Shares | 31.8.2026 | 1,692 | -1,692 | $241.39 |
| Hamill Laura | Tax Withholding in Shares | 31.8.2026 | 14 | -14 | $244.06 |
| RIEDEL NORBERT G | Tax Withholding in Shares | 31.8.2026 | 14 | -14 | $244.64 |
| ENRIGHT PATRICK G | Tax Withholding in Shares | 31.8.2026 | 14 | -14 | $244.64 |
| Henderson Mary Elizabeth | Tax Withholding in Shares | 31.8.2026 | 16 | -16 | $244.64 |
| Hamill Laura | Tax Withholding in Shares | 31.8.2026 | 1,692 | -1,692 | $241.39 |
| Winningham Rick E | Tax Withholding in Shares | 31.8.2026 | 1,692 | -1,692 | $241.39 |
| COZADD BRUCE C | Tax Withholding in Shares | 31.8.2026 | 1,209 | -1,209 | $241.39 |
| Iannone Robert | Open Market Sale | 27.8.2026 | 124,420 | -18,187 | $247.86 |
| Iannone Robert | Exercise of Derivative Securities | 27.8.2026 | 142,607 | +2,916 | $137.12 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
4,624,690 shares short as of 2026-08-31 · vs. 3,355,182 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
66.6% of trading volume this week was short selling, vs. 61.0% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology